Scancell Holdings PLC

SCP

Company Profile

  • Business description

    Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

  • Contact

    Sanders Road
    Unit 202, Bellhouse Building
    Oxford Science Park
    OxfordOX4 4GD
    GBR

    T: +44 1865582066

    https://www.scancell.co.uk

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 April 2025

    Employees

    58

Stocks News & Analysis

stocks

Signs of a turnaround for undervalued ASX share

Market likes the payoff from early efforts at reining in costs.
stocks

Australia has the highest dividend yields in the world, so why the endless chase for even higher yields?

Ashley Owen explores why investors' insatiable thirst for higher yields leads to unnecessarily complicating their portfolio.
stocks

Investing in gold miners

Exploring the commodity as prices continue to soar. 

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,825.1020.900.24%
CAC 408,178.5414.430.18%
DAX 4022,513.4298.60-0.44%
Dow JONES (US)44,546.08165.35-0.37%
FTSE 1008,732.4632.26-0.37%
HKSE22,620.33805.963.69%
NASDAQ20,026.7781.130.41%
Nikkei 22539,149.43312.04-0.79%
NZX 50 Index12,989.1883.200.64%
S&P 5006,114.630.44-0.01%
S&P/ASX 2008,555.8015.800.19%
SSE Composite Index3,346.7214.240.43%

Market Movers